

Costs of typhoid vaccination for international travelers from the United States

Authors:

Heesoo Joo, PhD^{1*}; Brian A. Maskery, PhD¹; Louise K. Francois Watkins, MD, MPH²;

Joohyun Park, PhD¹; Kristina M. Angelo, DO, MPH&TM²; Eric S. Halsey, MD¹

Affiliations:

¹ Division of Global Migration Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

² Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Running head: Cost of typhoid vaccination in the United States

Key words: typhoid fever, typhoid vaccination, vaccination costs

Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention (CDC).

^{1*} Address: U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS H16-4, Atlanta, GA 30329, USA; Phone number: +1 404 718 1667; e-mail: hjoo@cdc.gov

1 **Abstract**

2 In the United States, typhoid vaccination is recommended for international travelers to
3 areas with a recognized risk of typhoid exposure. Using MarketScan® Commercial Database
4 from 2016 through 2022, we estimated typhoid vaccination costs by route (injectable vs. oral)
5 and provider setting (clinic vs. pharmacy). Of 165,930 vaccinated individuals, 99,471 received
6 injectable and 66,459 received oral typhoid vaccines, with 88% and 17% respectively
7 administered at clinics. Average costs for injectable vaccination were \$132.91 per person [95%
8 confidence interval (CI): \$132.68–\$133.13], with clinic and pharmacy costs at \$136.38 [95% CI:
9 \$136.14–\$136.63], and \$107.45 [95% CI: \$107.13–\$107.77] respectively. Oral vaccination costs
10 averaged \$81.23 per person [95% CI: \$81.14–\$81.33], encompassing \$86.61 [95% CI: \$86.13–
11 \$87.10] at clinics and \$80.14 [95% CI: \$80.09–\$80.19] at pharmacies. Out-of-pocket costs
12 comprised 21% and 33% of total costs for injectable and oral vaccinations. These findings may
13 inform clinical decision-making to protect international travelers' health.

14 **1. Introduction**

15 Typhoid fever has been estimated to cause 9.2 million cases per year worldwide,
16 resulting in 110,000 deaths in 2019, with the highest incidence rates estimated for the World
17 Health Organization South-East Asian, Eastern Mediterranean, and African regions [1, 2]. In the
18 United States, typhoid fever is rare, mostly linked to travel to endemic countries [3-5]. During
19 2017–2019, approximately 400 cases were reported annually in the United States, with over 80%
20 associated with international travel [6]. In 2020, cases decreased to 157 due to limited
21 international travel during the COVID-19 pandemic [3].

22 In the United States, the Advisory Committee on Immunization Practices recommends
23 typhoid vaccination for international travelers to areas with a recognized risk of typhoid
24 exposure [7]. Accordingly, the U.S. Centers for Disease Control and Prevention (CDC)
25 recommends typhoid vaccination for those traveling to most areas in Latin America, Africa, and
26 Asia [7-9]. Currently, two vaccines, Typhim Vi[®] (Typhoid Vi Polysaccharide Vaccine) and
27 Vivotif[®] (Typhoid Vaccine Live Oral Ty21a), are available in the United States [9]. Typhim Vi[®]
28 can be administered to individuals at least two years old. It is a single dose (injection) and should
29 be administered at least two weeks before travel [9]. Vivotif[®] is suitable for individuals six years
30 or older and requires one capsule every other day (total: four capsules) to be completed at least
31 one week before travel [9]. Booster doses are recommended every five years for oral vaccines or
32 every two years for injectable vaccines to maintain protection [9, 10].

33 While typhoid vaccination is considered a cost-effective or cost-saving strategy in some
34 endemic areas with high incidence rates of typhoid fever [11, 12], its cost-effectiveness for U.S.
35 residents who travel internationally remains understudied. This analysis provides the first steps

36 toward evaluating cost-effectiveness by using claims data to estimate typhoid vaccination cost
37 per individual by vaccination route of administration and provider setting.

38 **2. Materials and methods**

39
40 We identified typhoid vaccine recipients between January 1, 2016, and December 31,
41 2022, in the Merative® MarketScan® Commercial Database using an online tool, MarketScan®
42 Treatment Pathways. Individuals receiving injectable typhoid vaccines were identified using the
43 Current Procedural Terminology (CPT) code 90691 or drug product name “Typhim Vi,” while
44 oral vaccine recipients were identified using CPT code 90690 or drug product name “Vivotif.”

45 We excluded individuals with (1) capitated health plans, (2) Medicare, (3) duplicate
46 vaccine procedure code and drug name on the same day (i.e., those with MarketScan® records of
47 receiving typhoid vaccine both at a clinic and a pharmacy) to avoid double-counting services, (4)
48 age below vaccine-specific minimum age requirements (i.e., younger than two years for
49 injectable and younger than six years for oral vaccine), (5) zero total typhoid vaccine payments,
50 and (6) outlier typhoid vaccine payments using 1.5 interquartile ranges (IQR) (Appendix Figures
51 1 and 2). We excluded individuals enrolled in capitated health plans or Medicare due to limited
52 payment information associated with each claim.

53 We categorized individuals by route of administration (injectable vs. oral) and provider
54 setting (clinics vs. pharmacies). For those vaccinated at pharmacies, payments included only
55 vaccine costs because pharmacies do not charge separately for administration. However, clinic
56 payments may or may not include vaccine administration payments in addition to vaccine
57 payments.

58 Thus, we divided the clinic sample into two subgroups. Sub-sample A included
59 individuals receiving typhoid vaccine at clinics without corresponding CPT codes for vaccine
60 administration (90460, 90461, 90471 or 90472 for injectable; 90460, 90461, 90473 or 90474 for
61 oral) on the same day as their typhoid vaccine CPT codes or individuals who had vaccine
62 administration codes but zero or missing total payments for vaccine administration (i.e., invalid
63 payments). Around 11% of injectable typhoid vaccine recipients and 73% of oral typhoid
64 vaccine recipients at clinics either lacked corresponding CPT codes for vaccine administration or
65 had invalid vaccine administration payments (Appendix Figures 1-A and 2-A). Clinics may not
66 charge for oral typhoid vaccine administration because patients will complete the oral vaccine
67 schedule at home. Sub-sample B included typhoid vaccine recipients at clinics with non-zero
68 vaccine administration payments on the same day. Additionally, for clinic sub-sample B, we
69 excluded outliers for vaccine administration payments using 1.5 IQR. This sample division
70 helped to distinguish between clinics that charged for expected vaccine administration and
71 clinics that did not charge for administration.

72 We examined demographics and estimated the average typhoid vaccination costs per
73 person per administration by vaccination route and provider setting, using Stata SE 16.1. P-
74 values below 0.01 indicated rejection of the null hypothesis (i.e., no difference between groups).
75 Categorical variables (i.e., sex, age group, and living area) were assessed using Pearson's chi-
76 square tests, while continuous variables (i.e., age and payments) were analyzed using two-sample
77 t-tests with unequal variances.

78 Reported payments, including insurance reimbursements and patients' out-of-pocket
79 payments, represent vaccination costs from the payer perspective throughout the manuscript.
80 Typhoid vaccination costs, except for those in clinic sub-sample B, included only typhoid

81 vaccine costs. Typhoid vaccination costs for clinic sub-sample B included both typhoid vaccine
82 and vaccine administration costs. All costs were adjusted to 2022 U.S. dollars using the
83 Consumer Price Index for medical care [13]. A CDC reviewer determined that the project, which
84 used only deidentified data, did not meet the regulatory definition of human subject research and
85 did not need institutional board review.

86 **3. Results**

87 We identified 165,930 individuals who received a typhoid vaccine between 2016 and
88 2022 in the United States, with 99,471 (60%) receiving the injectable vaccine and 66,459 (40%)
89 receiving the oral vaccine (Table 1). Among injectable vaccine recipients, 88% (N=87,524)
90 received it at a clinic, while the remaining 12% (N=11,947) received it at a pharmacy. Regarding
91 the oral vaccine, 17% (N=11,239) received it at a clinic, while 83% (N=55,220) received it at a
92 pharmacy.

93 About 55% of typhoid vaccine recipients were female (Table 1). Injectable typhoid
94 vaccine recipients were significantly younger (31 years) compared to oral vaccine recipients (36
95 years) ($p<0.01$). Injectable vaccine recipients at pharmacies were significantly older than
96 recipients at clinics (35 years vs. 31 years old; $p<0.01$). Conversely, individuals receiving oral
97 vaccines at pharmacies were younger than those at clinics (35 years vs. 36 years old; $p<0.01$).
98 Oral vaccine recipients were significantly more likely to have rural residency than injectable
99 vaccine recipients (5.6% vs. 4.2%; $p<0.01$). Injectable vaccine recipients at pharmacies were
100 more likely to reside in rural areas than those at clinics (5.9% vs. 4.0%; $p<0.01$). However,
101 individuals receiving oral vaccines at pharmacies were less likely to reside in rural areas than
102 those at clinics (5.3% vs. 6.8%; $p<0.01$).

103 On average, the total cost associated with injectable typhoid vaccine, including out-of-
104 pocket and insurance costs, was \$132.91 per person [95% confidence interval (CI): \$132.68–
105 \$133.13] (Table 2). The average total cost to receive an injectable vaccine at a clinic was
106 \$136.38 per person [95% CI: \$136.14–\$136.63]. The average total costs were \$116.07 [95% CI:
107 \$115.46–\$116.68] for clinic sub-sample A and \$138.90 [95% CI: \$138.64–\$139.16] for clinic
108 sub-sample B. Costs for clinic sub-sample B included \$106.25 [95% CI: \$106.06–\$106.45] for
109 vaccines and \$32.65 [95% CI: \$32.53–\$32.76] for vaccine administration. The cost per person
110 vaccinated at pharmacies was \$107.45 [95% CI: \$107.13–\$107.77].

111 The average total cost associated with oral typhoid vaccination was \$81.23 per person [95%
112 CI: \$81.14–\$81.33]. The cost at clinics was \$86.61 per person [95% CI: \$86.13–\$87.10]. The
113 cost for clinic sub-sample A was \$79.60 [95% CI: \$79.11–\$80.08] and the cost for clinic sub-
114 sample B was \$106.39 [95% CI: \$105.45–\$107.33], including \$80.45 [95% CI: \$79.74–\$81.16]
115 for vaccine and \$25.93 [95% CI: \$25.43–\$26.44] for vaccine administration. The cost at
116 pharmacies was \$80.14 per person [95% CI: \$80.09–\$80.19].

117 The average of out-of-pocket cost associated with typhoid vaccination was \$28.43 per
118 person [95% CI: \$28.14–\$28.71] for an injectable vaccine and \$26.78 per person [95% CI:
119 \$26.53–\$27.03] for an oral vaccine (Table 2). Out-of-pocket costs constituted 21% of the
120 injectable vaccination cost and 33% of the oral vaccination cost. The highest average out-of-
121 pocket cost was \$60.30 [95% CI: \$59.15–\$61.46] for clinic sub-sample A with injectable vaccine,
122 while the lowest average out-of-pocket cost was \$18.14 [95% CI: \$16.96–\$19.32] for clinic sub-
123 sample B with oral vaccine.

124 **4. Discussion**

125 This study analyzed U.S. typhoid vaccination costs, which averaged around \$130 per
126 person for an injectable vaccine and \$80 per person for an oral vaccine. Compared to vaccines in
127 CDC’s adult and child/adolescent immunization schedules, which are largely covered by
128 insurance when provided by an in-network provider [14], typhoid vaccination tends to have
129 higher out-of-pocket costs since it is not included in these routine schedules and may not be
130 covered by health insurance plans. This is one of the first analyses to examine U.S. costs for a
131 vaccine that is not in the routine schedules. The high cost of typhoid vaccination and the
132 potential that typhoid vaccines may not be covered by health insurance could pose a barrier for
133 international travelers.

134 Considering vaccine cost is important during pretravel consultations. Areas with a
135 typhoid risk may also present other infectious disease concerns, such as malaria (requiring
136 malaria chemoprophylaxis) or yellow fever, etc. (necessitating additional vaccines). Knowing
137 approximate out-of-pocket costs for typhoid vaccination may assist healthcare practitioners in
138 prioritizing their recommendations.

139 Other factors may influence the decision to pursue typhoid vaccination. These include the
140 waning of typhoid vaccine efficacy over time and the lack of travelers’ knowledge about travel
141 medicine and typhoid vaccine. The estimated three-year cumulative efficacy of typhoid vaccine
142 is around 50% for a three-dose schedule of Ty21a vaccination and 55% for a single dose of Vi
143 polysaccharide vaccination [15]. For individuals who frequently travel to typhoid-endemic areas,
144 typhoid vaccination may result in recurring costs due to the recommendation of booster doses ,
145 adding to their financial burden.

146 Vaccine availability, typhoid fever incidence rates in destination countries, the time
147 required to complete immunization before travel, and the traveler’s medical history/age may

148 influence the decision to recommend injectable or oral typhoid vaccine. During the COVID-19
149 pandemic, Vivotif[®] was temporarily discontinued in the United States due to a substantial
150 decrease in international travel [16]. Consequently, travelers in 2021 could have only received
151 Typhim Vi[®] or forego vaccination (Appendix Table 1). Travelers planning trips to areas with
152 ongoing outbreaks or high incidence rates of typhoid fever—such as Bangladesh, India, and
153 Pakistan [17]—may benefit more from vaccination. The time before departure may influence
154 which vaccine is recommended to achieve optimal immune coverage during the trip [9]. If
155 travelers visit a travel health clinic less than one week before their trip, healthcare professionals
156 may not recommend typhoid vaccination. Also, injectable and oral typhoid vaccines have
157 different considerations based on minimum age requirements and an individual’s medical history
158 [9].

159 Individuals who received oral typhoid vaccine were older and more often lived in rural
160 areas. Younger urban individuals may have chosen pharmacies for oral vaccine administration to
161 avoid extra costs. Additional study is needed to clarify if vaccine cost influenced these patterns.

162 There are some limitations to this study. First, we did not include outpatient costs to visit
163 a travel health clinic because travelers would typically receive guidance for several travel-
164 associated health risks in addition to typhoid. Thus, our estimates likely underestimated the total
165 cost. We could not determine reasons for missing vaccine administration CPT codes. Individuals
166 lacking these codes on the day of the typhoid vaccination may have visited clinics where
167 administration fees are not charged or may have encountered coding errors. Finally, our sample
168 included only those with employer-sponsored private non-capitated health insurance covering
169 typhoid vaccination, excluding entirely out-of-pocket payers, which may be common given the
170 large number of fee-for-service U.S. travel clinics. Nevertheless, we found significant numbers

171 of individuals who received typhoid vaccine covered by their insurance to provide an estimate of
172 typhoid vaccination costs in the United States.

173

174 **5. Conclusions**

175 As international travel returns to pre-pandemic levels, the demand for travel-related
176 vaccination, including typhoid vaccination, is anticipated to rise. Travel-related typhoid
177 vaccination costs in the United States are crucial for informing clinical decision-making to
178 protect international travelers' health and evaluating cost-effectiveness of typhoid vaccination for
179 international travelers.

180

181 **Declaration of competing interest**

182 The authors affirm that they do not have any known financial interests or personal
183 relationships that could have influenced the work reported in this manuscript.

184 **Data availability**

185 The data utilized for this study are accessible from a third-party source, Merative®. Data
186 availability is subject to restrictions as the data were utilized under license. Therefore, these data
187 are not publicly accessible.

References

- [1] Hancuh M, Walldorf J, Minta AA, Tevi-Benissan C, Christian KA, Nedelec Y, et al. Typhoid Fever Surveillance, Incidence Estimates, and Progress Toward Typhoid Conjugate Vaccine Introduction - Worldwide, 2018-2022. *MMWR Morb Mortal Wkly Rep.* 2023;72:171-6.
- [2] Institute for Health Metrics and Evaluation. Typhoid fever-level 4 cause. Seattle, WA: Institute for Health Metrics and Evaluation, Global Burden of Disease Collaborative Network; 2020.
- [3] Centers for Disease Control and Prevention (CDC). National Typhoid and Paratyphoid Fever Surveillance Annual Report, 2020. 2023.
- [4] Lynch MF, Blanton EM, Bulens S, Polyak C, Vojdani J, Stevenson J, et al. Typhoid fever in the United States, 1999-2006. *JAMA.* 2009;302:859-65.
- [5] Papadimitropoulos V, Vergidis PI, Bliziotis I, Falagas ME. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. *Clin Microbiol Infect.* 2004;10:681-3.
- [6] CDC, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED). National Typhoid and Paratyphoid Fever Surveillance. 2023.
- [7] Jackson BR, Iqbal S, Mahon B, Centers for Disease C, Prevention. Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015. *MMWR Morb Mortal Wkly Rep.* 2015;64:305-8.
- [8] CDC, National Center for Immunization and Respiratory Diseases. Typhoid Vaccine Information Statement (VIS). 2019.
- [9] CDC, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Foodborne, Waterborne, and Environmental Diseases (DFWED). Typhoid Fever and paratyphoid Fever: Vaccination. 2023.
- [10] CDC, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Global Migration Health (DGMH) CDC Yellowbook 2024: Typhoid & Paratyphoid Fever - Prevention. 2023.
- [11] Bilcke J, Antillon M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, et al. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. *Lancet Infect Dis.* 2019;19:728-39.
- [12] Chauhan AS, Kapoor I, Rana SK, Kumar D, Gupta M, John J, et al. Cost effectiveness of typhoid vaccination in India. *Vaccine.* 2021;39:4089-98.
- [13] U.S. Bureau of Labor Statistics. CPI for All Urban Consumers (CPI-U): Medical care in U.S. city average, not seasonally adjusted Washington D.C.2023.
- [14] National Center for Immunization and Respiratory Diseases, CDC. How to pay for vaccines. 2023.
- [15] Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. *Cochrane Database Syst Rev.* 2018;5:CD001261.
- [16] U.S. Food and Drug Administration. CBER-Regulated Products: Resolved Shortages. 2023.
- [17] CDC, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Global Migration Health (DGMH) Typhoid fever: Who is at risk? 2023.

Table 1: Sample statistics for individuals receiving typhoid vaccine from MarketScan Commercial Claims Database using Treatment Pathways, 2016–2022

| | Typhim Vi® (Injectable) | | | | Vivotif® (Oral) | | | | p-value ^{2,4} |
|---------------------------------|-------------------------|--------------|---------------|------------------------|-----------------|---------------|---------------|------------------------|------------------------|
| | Clinic | Pharmacy | Total | p-value ^{2,3} | Clinic | Pharmacy | Total | p-value ^{2,3} | |
| Sample size, No. | 87,524 | 11,947 | 99,471 | N/A | 11,239 | 55,220 | 66,459 | N/A | N/A |
| Sex, No. (%) | | | | | | | | | |
| Female | 47,887 (54.7) | 6,503 (54.4) | 54,390 (54.7) | 0.56 | 5,996 (53.4) | 30,532 (55.3) | 36,528 (55.0) | <0.01 | 0.26 |
| Male | 39,637 (45.3) | 5,444 (45.6) | 45,081 (45.3) | | 5,243 (46.6) | 24,688 (44.7) | 29,931 (45.0) | | |
| Age (years), Mean (SD) | 30.9 (17.8) | 34.7 (16.5) | 31.3 (17.7) | <0.01 | 36.3 (16.0) | 35.3 (16.4) | 35.5 (16.3) | <0.01 | <0.01 |
| Age group, No. (%) | | | | | | | | | |
| Min. age ¹ –18 years | 25,584 (29.2) | 2,132 (17.9) | 27,716 (27.8) | <0.01 | 1,856 (16.5) | 10,714 (19.4) | 12,570 (18.9) | <0.01 | <0.01 |
| 19–39 years | 32,079 (36.7) | 4,995 (41.8) | 37,074 (37.3) | | 4,514 (40.2) | 21,279 (38.5) | 25,793 (38.8) | | |
| 40–64 years | 29,861 (34.1) | 4,820 (40.3) | 34,681 (34.9) | | 4,869 (43.3) | 23,227 (42.1) | 28,096 (42.3) | | |
| Living area No. (%) | | | | | | | | | |
| Rural | 3,505 (4.0) | 707 (5.9) | 4,212 (4.2) | <0.01 | 758 (6.8) | 2,934 (5.3) | 3,692 (5.6) | <0.01 | <0.01 |
| Non-rural | 76,489 (87.4) | 9,393 (78.6) | 85,882 (86.4) | | 8,669 (77.1) | 45,610 (82.6) | 54,279 (81.7) | | |
| Missing | 7,530 (8.6) | 1,847 (15.5) | 9,377 (9.4) | | 1,812 (16.1) | 6,676 (12.1) | 8,488 (12.8) | | |

Abbreviations: SD, standard deviation; N/A, not applicable

¹ Minimum age requirements are 2 years old for Typhim Vi® and 6 years old for Vivotif®.

² For age, p-values are calculated using the two-sample t-test with unequal variances. For all other variables, p-values are calculated using the Pearson’s chi-square test.

³ P-values compare sample characteristics between clinic and pharmacy samples for injectable and oral administrations, respectively.

⁴ P-values compare sample characteristics between total injectable and total oral samples.

Table 2: Costs associated with typhoid vaccination from the MarketScan Commercial Database in 2016–2022 (2022 USD)

| Vax | Payment | Clinic | | | | Pharmacy | p-value | Total | |
|--|---------------|-----------------------------|---------------------------------|--------------------------|-----------------------------|-----------------------------|-----------------------------|-------|-----------------------------|
| | | Sub-sample A (vax only) | Sub-sample B (vax and admin) | | | | | | |
| | | | Vax | Admin | Total | | | | |
| Typhim Vi [®] (Injectable) | N | 9,637 | 77,887 | | | 87,524 | 11,947 | N/A | 99,471 |
| | Out-of-pocket | \$60.30 [59.15–61.46] | \$24.69 [24.39–24.99] | \$0.91 [0.87–0.95] | \$25.60 [25.29–25.91] | \$29.42 [29.10–29.73] | \$21.15 [20.51–21.79] | <0.01 | \$28.43 [28.14–28.71] |
| | Insurance | \$55.77 [54.68–56.87] | \$81.56 [81.23–81.90] | \$31.74 [31.61–31.86] | \$113.30 [112.91–113.69] | \$106.97 [106.58–107.35] | \$86.30 [85.53–87.07] | <0.01 | \$104.48 [104.13–104.84] |
| | Total | \$116.07 [115.46–116.68] | \$106.25 [106.06–106.45] | \$32.65 [32.53–32.76] | \$138.90 [138.64–139.16] | \$136.38 [136.14–136.63] | \$107.45 [107.13–107.77] | <0.01 | \$132.91 [132.68–133.13] |
| Vivotif [®] (Oral) | N | 8,295 | 2,944 | | | 11,239 | 55,220 | N/A | 66,459 |
| | Out-of-pocket | \$28.18 [27.34–29.03] | \$17.50 [16.37–18.64] | \$0.64 [0.48–0.79] | \$18.14 [16.96–19.32] | \$25.55 [24.85–26.25] | \$27.03 [26.76–27.29] | <0.01 | \$26.78 [26.53–27.03] |
| | Insurance | \$51.41 [50.61–52.22] | \$62.95 [61.66–64.24] | \$25.30 [24.78–25.81] | \$88.25 [86.72–89.77] | \$61.06 [60.28–61.84] | \$53.11 [52.85–53.37] | <0.01 | \$54.45 [54.19–54.71] |
| | Total | \$79.60 [79.11–80.08] | \$80.45 [79.74–81.16] | \$25.93 [25.43–26.44] | \$106.39 [105.45–107.33] | \$86.61 [86.13–87.10] | \$80.14 [80.09–80.19] | <0.01 | \$81.23 [81.14–81.33] |

Abbreviation: Vax, vaccine; Admin, vaccine administration

Notes: The 95% confidence intervals are shown in squared parentheses. P-values compare total costs under the clinic and pharmacy settings using the two-sample t-tests with unequal variances.